PharmAsia News Business Bulletin
This article was originally published in Scrip
Executive Summary
A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.
You may also be interested in...
Indo-Turkish Biosimilar Connections Build
More Indian firms appear keen to target the Turkish market for biosimilars. After Dr Reddy's outlined its plans earlier this year, Zydus Cadila has now firmed up an alliance with Turkey's Eczacibasi Ilac Pazarlama AS for biosimilars especially in the oncology segment.
Indo-Turkish Biosimilar Connections Build
More Indian firms appear keen to target the Turkish market for biosimilars. After Dr Reddy's outlined its plans earlier this year, Zydus Cadila has now firmed up an alliance with Turkey's Eczacibasi Ilac Pazarlama AS for biosimilars especially in the oncology segment.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.